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❚ Abstract
Although small-bowel tumors are a small proportion of
gastrointestinal neoplasms recent studies suggest that the
incidence of these diseases is increasing. In fact, using new
diagnostic modalities, their frequency has been shown to be
slightly superior than previously thought. Until recently, diagnosis
and management of these tumors were delayed by the difficult
of access to the small bowel and the poor diagnostic capabilities
of the available diagnostic techniques. An array of new methods
has recently been developed, increasing the possibility of detec-
ting these tumors at an earlier stage. In this particular subset of
patients capsule endoscopy, despite its possible limitations,
may provide crucial information changing the subsequent
patient management and possibly influencing the long-term
clinical outcome.
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❚ Résumé
Bien que les tumeurs de l’intestin grêle ne représentent qu’une
faible proportion des lésions néoplasiques du tractus digestif, de
récentes études ont mis en évidence une légère augmentation de
leur incidence. En fait, grâce aux nouvelles modalités diagnos-
tiques, leur fréquence s’est avérée légèrement supérieure à ce qui
était précédemment rapporté. Jusqu’à très récemment, le
diagnostic et la prise en charge de ces tumeurs étaient retardés
en raison d’un accès difficile à l’intestin grêle et aux faibles
capacités diagnostiques des moyens techniques disponibles.
Tout un éventail de nouvelles méthodes ont récemment été mises
au point, améliorant la possibilité de détecter ces lésions à un
stade plus précoce. Pour cette catégorie spécifique de patients
avec lésions de l’intestin grêle, la capsule endoscopique, en dépit
de ses limites, peut fournir une information cruciale influant par
conséquent sur la prise en charge du patient et sur les résultats
cliniques au long cours.
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❚ Introduction
Tumors of the small intestine present a unique challenge to the
clinicians across medical specialties. Although the small bowel
represents 75% of the length and 90% of the overall mucosal
surface of the alimentary tract and despite its anatomic location
between two regions of high cancer risk, the small bowel is
generally considered as a rare location for the development of
neoplasms, accounting for only 1-3% of all primary gastro-
intestinal (GI) tumors [1-3].
The overall age-adjusted incidence of small-bowel cancers
estimated in population based studies in Western countries
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lymphomas [1,11]. One reason why adenocarcinomas tend to
arise in the duodenum may implicate bile or its metabolites in the
etiology of the neoplasm at this site [16]. However, among patients
with Crohn’s disease, which generally affects the ileum rather than
the more proximal small bowel, adenocarcinomas tend to occur
in the terminal ileum [1].
Secondary neoplastic involvement of the small intestine has been
reported to be more frequent than primary small intestinal
neoplasms. Primary tumors of the colon, ovary, uterus, and
stomach can involve the small bowel (by direct invasion or by
intraperitoneal spread) whereas primaries from breast, lung, and
melanoma metastasize to the small bowel by the haematogenous
route [17]. Small bowel metastases from melanoma have been
described in 1.5-4.4% of patients [18,19] with previously removed
skin melanoma and in 58% of post-mortem specimens [18].
In the majority of cases, the diagnosis of small-bowel tumors is
delayed. This could be due to several factors:
– small-bowel tumors grow slowly, extraluminally, remaining
asymptomatic for years or presenting insidiously with non-
specific complaints such as abdominal pain, diarrhea, iron
deficiency anemia, bleeding, extra intestinal symptoms
(flushing, para-neoplastic syndromes) [20]. Obstruction is also
a common presentation; indeed, small-bowel tumors are the
third most common cause of small-bowel obstruction in the
United States [21];
– the rare incidence of small-bowel tumors may contribute to the
relatively low index of clinical suspicion for their presence;
– routine laboratory tests and other diagnostic tests may
frequently be inconclusive; as a consequence, diagnostic
laparoscopy or exploratory laparotomy may be indicated not
only to deliver an effective treatment but also to reach a
definitive diagnosis.
Since the introduction in clinical practice of capsule endos-
copy (CE), several case reports describing primary and secondary
tumors affecting the small bowel have been published. More
recently, a few retrospective studies collecting series of patients in
which this technology was able to show the presence of a small-
bowel tumor have also been published. On the other hand, recent
studies also suggest that some new techniques, other than
ranges between 0.9 and 1.4 (Table 1) [1,4-9]; malignant tumors
account for about one half of all new cases of small-bowel tumors
reported [10]. The incidence rate of small-bowel cancer varies
among populations: cancer rates are high among the Maori of
New Zealand (about 4 cases per 100.000 per year) and among
ethnic Hawaiians, and low in India, Romania, and other parts of
Eastern Europe [1]. Some recently published studies reported an
increasing incidence of these neoplasms over the last 20 years.
Bilimoria et al. [11] reported that, in the United States, the
incidence of small bowel tumors increased from 11.8 cases
per million in 1973 to 22.7 cases per million in 2004.
Because small-bowel tumors are relatively rare compared with
other neoplasms of the gastrointestinal tract, several factors have
been proposed to explain or understand this disparity: 1) a quick
transit allowing only short contact of possible carcinogens from
food with the intestinal mucosa; 2) the intestinal content is mixed
together with a great volume of intestinal juices decreasing the
concentration of irritating agents; 3) a decrease in mechanical
and/or chemical inflammation of the mucosa because of the
liquidity and alkaline pH of the small-bowel contents; 4) the high
concentration of lymphatic tissue and of immunoglobulin exerts
an effective immune surveillance; 5) the low bacteria concen-
tration in the small intestine processing the intestinal content
produces a low amount of carcinogens; 6) the rapid turnover of
epithelial cells should decrease the potential growth and develop-
ment of neoplastic cells [1,10-12].
Genetics could also play a role in some particular subgroups of
patients; subjects affected by familiar adenomatous polyposis,
Lynch syndrome, Crohn’s disease, celiac disease, Peutz-Jeghers
syndrome, and several other diseases must be surveyed for the
risk of small intestine tumor [9,13,14].
Approximately 40 different histological types of small intestinal
tumors have been identified [15]. Among malignant tumors, about
30-50% are adenocarcinomas, 25-30% are carcinoids, and
15-20% are lymphomas. A recently published study, including
1260 cases of small-bowel tumor, showed that they seem to be
frequently located in the ileum (about 30% of cases) or in the
duodenum (about 25% of cases) [9]; the sites at highest risk for
malignant neoplasms have been reported to be the duodenum
for adenocarcinomas and the ileum for carcinoids and
Table 1. Incidence of small-bowel tumors (modified from Neugut AI et al. [1])
Population/area Ref. Time interval Cases of SB tumour
Incidence
per million
Los Angeles County 4 1972-1985 264 -
Nine SEER Registers 5 1973-1982 366 9,6
Cancer register of British Columbia, Alberta, Saskatchewan, Manitoba 6 1975-1989 263 11
Utah Cancer registry 7 1966-1999 442 14
Nine SEER registers 8 1973-1991 892 13
Connecticut Tumor registry 9 1980-2000 1 260 8,8
National Cancer Database and Surveillance Epidemiology and End Results 11 1973-2004 67 843 11,8-22,7
SEER: Surveillance Epidemiology and End Result
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Authors also confirmed that the main clinical indication for CE in
patients with small-bowel tumors is obscure GI bleeding (in about
90% of cases). Other indication for CE in both these studies were:
chronic diarrhea, abdominal pain, para-neoplastic syndromes or,
in a small group of patients, presence of conditions increasing the
risk to develop a small-bowel tumor (such as refractory celiac
disease, familial adenomatous polyposis or Peutz-Jeghers
syndrome). In some rare cases CE was also used to confirm the
presence of a tumor previously suspected by other imaging
modalities. Although Cobrin et al. [30] underlined that in their
study the percentage of patients with tumor was greater among
patients younger than 50 years, the median age of patients
enrolled the above mentioned large studies ranged between
59 years [39] and 63 years [30], (Table 3).
Confirming data previously reported in surgical series [9,10] the
majority of tumors identified by CE (from 63% [31] to 86% [38])
are malignant neoplasms and the most frequent histological types
are adenocarcinomas, carcinoids (in about 20% of cases
each [30,31,34]), and GISTs. Of note, this tumor accounted for
more than one third of all collected cases in the large multi-center
European study [39]. As far as small-bowel metastases are
concerned, these lesions mainly (about 1/3 of cases [39]) derived
from previously removed skin melanomas [44], but there are also
some papers reporting lesions derived from colorectal
cancers [31], from hepatocellular carcinoma or from rare tumors
such as seminomas [39].
Small-bowel tumors appear at CE as masses (Fig. 1) or polyps in
about 70-80% of cases [31-39] and as ulcers (Fig. 2) (sometimes
actively bleeding) or stenoses in 20-30% of cases. Unfortunately,
it is not possible to determine pathology and tumor type based on
the capsule endoscopic appearance of lesions. These tumors are
located, based on the capsule transit time, in about 50% of cases
in the mid- or distal small bowel [31-39]. This could be a partial
explanation of the extensive (and mainly negative) diagnostic
work-up performed in patients enrolled in all these studies. Each
patient underwent a mean of 2-4.6% [31,34] examinations before
capsule endoscopy, specifically designed for the study of the
small bowel, have been introduced in clinical practice [22-27].
❚ Capsule endoscopy in the diagnosis
of small-bowel tumors
In a recently published paper, the hypothesis of an increased
incidence of small-bowel tumors in recent years was put forward,
based on the increasing number of cases diagnosed by means a
non-invasive methods such as CE and small-bowel ultra-
sound [28]. In fact, compared with previously mentioned
diagnostic techniques for the study of the small bowel, CE seems
to be an ideal tool to recognize the presence of neoplastic lesions
along the small bowel. The potential of CE for the diagnosis of
small-bowel tumors, as well as for the surveillance of subjects at
increased risk of developing them, depends largely on the tech-
nical characteristics of this diagnostic device. CE is a non-invasive
tool, well accepted by patients, which can allow for the visualiza-
tion of the entire small bowel; high-quality images of the small-
bowel mucosa may be captured and small and flat lesions
recognized, without exposure to radiation.
In fact, since the introduction of CE in clinical practice, some
studies have been published [29,30-34,39,40,44-45] reporting a
frequency of small-bowel tumors higher than previously expected,
ranging between 2.4% and 11%. One study [32] reported a
prevalence of small bowel tumors in patients undergoing CE
higher than 30%; however in this paper the Authors described
lesions as “tumour” without histological confirmation. Two recent
studies, coming from the USA and Europe, one of them published
only in abstract form [38,39], examined large populations of
patients undergoing CE (respectively 2000 [38] and more than
5000 cases [39]) in whom the definitive diagnosis was confirmed
by means of tissue sampling (Table 2). They both reported a
small-bowel tumor frequency of 2.4%, only slightly above that
reported in previous surgical series. In both these papers the

















Cobrin et al. [30] 562 50 (8.9) 63 48 0
Bailey et al. [31] 416 27 (6.3) 61 63 11.5
Estevez et al. [32] 320 23 (7.8) 63 NA NA
Urbain et al. [33] 443 11 (2.5) 63 100 0
Schwartz et al. [34] NA 87 (NA) 60 60 NA
Spada et al. [35] 280 13 (3.4) 58 77 23
Trifan et al. [36] 102 5 (4.9) 55 NA 0
Pasha et al. [38] 2000 45 (2.4) 62 66 17
Rondonotti et al. [39] 5129 124 (2.4) 59 NA 9.7
NA: not applicable (these data are not reported in the paper)
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CE while, focusing only on exams addressed to evaluate the small
bowel (particularly small-bowel series and/or small-bowel follow-
through and/or PE and/or CT-enteroclysis), the mean number of
examinations performed per patient ranged between
1 and 2 [30,31,34]. Despite the extensive number of examinations
performed before CE, this technique was found to have a positive
impact on diagnosis (defined as the capability to identify a
neoplasm not shown by other diagnostic techniques or as the
ability to provide crucial information leading to change the subse-
quent patient management) in about 65-80% of cases [33,39].
Urbain et al. [33], trying to evaluate the impact of CE on the thera-
peutic choices of malignant small-bowel tumors, found that CE
may influence directly the therapeutic work-up in about 55% of
cases by providing information about size, location and appea-
rance of the lesion.
❚ Impact of capsule endoscopy
on clinical outcomes
Because the early diagnosis and treatment of cancer usually
affects outcome, some Authors [30,31] suggest that the capa-
bility of CE to discover small-bowel tumors at an early stage may
have an impact on prognosis for patients with these lesions. In
addition, several papers revealed that advanced clinical stage and
large tumor size contributed to worse prognosis while the
identification and subsequent surgical treatment of the primary
tumour led to better prognosis [40].
All the papers previously mentioned reported that in patients with
small-bowel neoplasm identified by CE, surgery alone or surgery
plus chemotherapy is the treatment of choice in about 68-90% of
cases [30-32,38,39]. Nevertheless, recent studies [38] showed
that the identification of the small bowel tumor with CE can also
lead to less invasive procedures such as polypectomy, endos-
copic mucosal resection or chemotherapy alone.
Unfortunately, up to now, data about long-term clinical outcomes
of small bowel tumors diagnosed by CE are scarce.
Bailey et al. [31] reported that surgical treatment was performed
in 88% of patients with small-bowel tumor, in half of the cases
with curative aim: none of the patients who underwent a curative
resection developed tumor recurrence at follow-up (ranging from
26 to 51 months). Pasha et al. [38] reported that 36% of patients
with malignant tumour diagnosed with CE and followed prospec-
tively for more than 24 months remained recurrence free.
❚ Capsule endoscopy for specific
small-bowel tumors
Thanks to its capability to identify a small-bowel lesion in most
patients with a prior negative diagnostic work-up, several case
reports, but also some small series, aimed at evaluating the
possible role of the CE in the diagnosis of specific tumors in
particular clinical conditions, have been published over the last
few years.
Table 3. Frequency of capsule retention in patients undergoing capsule
endoscopy (modified from Pennazio M. [60])
Clinical Indication Frequency of capsule retention %
Healthy volunteers 0
Obscure GI bleeding 1.5
Suspected Crohn’s disease 1.4
Known Crohn’s disease 4-13
Small-bowel tumor 10-17
Suspected small-bowel obstruction 21
Figure 1
Submucosal jejunal mass with central ulcer. Histology revealed a GIST
Figure 2
Small bowel ulcers in a patient diagnosed with small-bowel lymphoma
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Lymphomatous polyposis (LP) first described by Cornes in
1961 [48,49] is a rare condition, however, since the introduction of
CE and balloon-assisted enteroscopy (BAE) in clinical practice, a
few reports [49,50] have been published on this topic. LP is defined
as polypoid mucosal involvement of long segments of the GI tract
by neoplastic lymphoid cells [49-51]. For many years LP has been
considered the macroscopic appearance of the mantle cell
lymphoma, but it has recently been suggested that it can be also
the macroscopic manifestation of mucosa-associated lymphoid
tissue (MALT) lymphoma and follicular B cell lymphoma [52]. In
patients with LP, CE is a valuable tool because it may recognize the
presence of nodules, evaluate the extent of the small-bowel invol-
vement and drive further investigations (i.e. the decision about the
BAE approach). In a recently published paper Akamatsu et al. [53]
suggested that, in patients with diagnosis of follicular lymphoma, a
complete evaluation of the entire small bowel before starting the
treatment is mandatory in order to discover multifocal lesions; this
should be achieved by CE or BAE.
Another peculiar clinical condition is represented by patients with
refractory celiac disease. It is known that these patients have an
increased risk to develop small-bowel neoplasms, mainly entero-
pathy associated T-cell lymphoma (EATL). However, in this
particular subgroup of patients CE is aimed at identifying not only
a malignant neoplasm but also some other possible compli-
cations such as ulcerative jejunitis. To date, two papers have been
published on this topic [54,55] showing that CE is a useful tool
in the assessment of complicated celiac disease, especially
in patients with refractory celiac disease type II [54].
Interestingly Ronchi et al. [56] reported an increased preva-
lence (14%) of small bowel tumours detected by CE in patients
with acromegaly. Although this study seems to be noticeably
biased (there was no histological confirmation of lesions identified
by CE) it opens up a new frontier in the field of cancer prevention-
surveillance in patients with increased risk of malignancies.
❚ Capsule endoscopy: risks
and limitations in patients
with small-bowel tumors
Several papers [57-58] described risks and limitations related to
the use of CE in everyday clinical practice. Some limitations can
be present in any procedure performed regardless of the clinical
indication (“general limitations”); these limitations are mainly
related to the technical characteristics of the device or to the
anatomical structure of the small bowel: i.e. due to the length of
the small bowel, the capsule allows an evaluation of the entire
small bowel only in 75-85% of cases [57,59]; in the recently
published systematic review the overall completion rate was
83.5% while in patients undergoing CE because of small bowel
tumors it was 85.6%. In addition, sometimes, the presence of
fecal debris, particularly in the distal small bowel, may hamper the
accurate visualization of the small-bowel mucosa.
In the last few years several papers [41-43] suggested an
increased survival for patients with neuroendocrine tumor metas-
tasis when the primary tumor is identified and resected. van
Tuyl et al. [44], in a prospective descriptive study, evaluated
20 patients with liver metastases, mesenteric metastases or both,
originated from a neuroendocrine tumor (NET) with unknown
primary location. All these patients had undergone several
examinations including small-bowel enteroclysis, abdominal CT,
pentetreotide scintigraphy and laboratory tests. In this particular
subset of patients, CE showed a diagnostic yield (60%) signifi-
cantly higher than enteroclysis and CT scan. Pentetreotide scinti-
graphy had an even higher diagnostic yield than CE but without
differentiation between intestinal and mesenteric localization. In
this study, the absence of findings at CE in patients with abnor-
malities at nuclear imaging was interpreted to be related to the
presence of NET restricted to the mesentery or to a false-negative
CE. On the ground of these data, the Authors suggested that
patients with a metastatic NET and an unknown primary tumor
should undergo CE. Conversely, in a small retrospective study of
8 patients [45], CE detected NETs of the small bowel with high
specificity but slightly lower sensitivity than did CT enteroclysis. It
was concluded that CE should not be used as a routine method
for diagnosing NET in the small bowel.
As far as small-bowel metastases are concerned, Prakoso and
Selby [46] performed a retrospective analysis of a prospective
database identifying 13 patients with previous or recurrent mali-
gnant melanoma referred for CE. The indication for CE were overt
GI bleeding in three patients, anemia in six, abnormal imaging in
two, abdominal pain in one, and one patient had positive fecal
occult blood test. In these patients CE was able not only to show
small-bowel metastases (in 5 patients) but also to provide a diffe-
rent possible explanation of symptoms in three other patients
(NSAID-related ulcers, artero-venous malformation or aphtoid
lesions). The Authors concluded that since the optimal investiga-
tion for the detection of small-bowel metastases in patients with
melanoma has still to be determined, CE can be considered an
ideal method to do so because it appears to be more sensitive
than small-bowel follow-through and CT scan.
Flieger et al. [47] explored the potential contribution of CE to the
diagnosis and staging of gastrointestinal lymphomas describing
capsule endoscopic features of these tumors. They studied with
CE a total of 27 consecutive patients with newly diagnosed gastro
intestinal lymphoma: 20 patients with histologically confirmed
gastric lymphoma and seven patients with intestinal lymphoma.
All seven patients with primary intestinal lymphomas were found
to have pathological findings at CE (ulcerations, nodules or villous
atrophy), while 5 of the 20 patients with gastric lymphoma had
pathological findings in the small bowel (including abnormal villi,
white nodules or villous atrophy). In this study, the Authors found
that CE is able to identify pathological intestinal findings in patients
with gastrointestinal lymphoma more frequently than previously
thought and suggest that knowledge of small-bowel involvement
can lead to changes in the therapeutic strategy in individual
cases.
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Unfortunately, in the field of small-bowel neoplasms, in addition to
these general limitations there are some other related to the
intrinsic characteristics of these lesions (“tumor-related limita-
tions”).
Several studies [75-77] reported patients with negative CE in
whom further examinations showed small-bowel tumors (false
negative capsule endoscopy). Lewis et al. [76], analyzing data
from an industry-maintained trial database, found that in
about 1.5% of patients with small-bowel tumors CE was comple-
tely negative. These authors estimated that the miss rate of CE in
neoplastic diseases can reach 18.9%. Although this percentage
is substantially lower than that reported in the same paper for
other diagnostic techniques (63.2%) it remains still alarming,
especially if one keeps in mind the clinical relevance of these miss
findings. In addition, recent reports showed a relatively low sensi-
tivity of CE when compared with CT enterography [78]. Obviously,
there are several reasons contributing to that miss rate but
probably the crucial one is related, in this particular subset of
patients, to the fact that sometime it is arduous, on the ground of
CE findings, to discriminate masses from bulges. A bulge is
defined as a round smooth, large base protrusion in the lumen
having an ill defined edge on the surrounding mucosa; it can be a
prominent normal fold or the luminal expression of intestinal loop
angulation and stiffness, and sometimes it can be virtually indis-
tinguishable from a small submucosal tumor. Some visual clues
may help distinguishing masses from bulges (i.e. changes in
mucosal characteristics, presence of bridging folds, of transit
abnormalities, of repetitive images, and of synchronous lesions).
Recently, Shyung et al. [79] proposed, on the ground of these
visual clues, a simple scoring system to distinguish masses from
bulges. Unfortunately this has not been validated yet in clinical
practice. Moreover, in everyday clinical practice, these indicators
are often completely lacking.
Pasha et al. [38] described 51 patients with polypoid lesions
revealed at CE that were not confirmed at further examinations
(false positive capsule endoscopy). This problem, highlighted also
in other studies [32], can significantly influence the subsequent
management: in fact a positive CE requires further invasive exami-
nations (BAE or surgical interventions). For this reason the final
interpretation of a finding identified by CE must be done taking
into account not only the endoscopic images but also the patient’s
clinical history and other diagnostic examinations performed. On
the other hand, as largely discussed, CE has some technical and
practical limitations; therefore, mainly in the field of small bowel
neoplasm, it should be complementary to other diagnostic tech-
niques such as CT enterography or BAE.
❚ Capsule endoscopy in inherited
polyposis syndromes
On the ground of its own technical characteristics (i.e. high-quality
endoscopic images of the whole small bowel, no need for
radiations) and of the patients’ acceptance, CE has also been
Among general limitations, capsule retention is certainly the most
feared one because it can significantly modify the subsequent
management of the patient. It is generally recognized that the
frequency of capsule retention is mostly dependent on the clinical
indication to CE (Table 3), ranging between 0% in healthy subjects
to 21% in patients with intestinal obstruction [60,61]. Patients with
small-bowel tumors, which frequently appear as lesions protru-
ding into the small-bowel lumen or as stenoses, in both cases
capable of narrowing the lumen of the small bowel, have a high
probability to develop capsule retention. The recent systematic
collection of Liao et al. [62] reports a retention rate in patients
undergoing CE for small bowel tumors of 2.1%, which is closely
similar to that observed in patients examined for obscure GI blee-
ding. However, in the larger studies especially focused on small
bowel tumors, capsule retention seems to be a frequent situation
that can occur in 10-17% of patients (table 2). Nevertheless
most Authors consider this situation as a minor complication
(Zmora et al. defined this as a “fortunate” complication [63]). In
fact, although possible acute obstruction due to capsule retained
at the site of the tumor has been reported [64-65], this is an extre-
mely rare event and does not represent a contra-indication in itself
to CE. In these patients the subsequent surgical intervention,
allowing capsule retrieval, was planned basically to treat the tumor
rather than to retrieve the capsule. We must also keep in mind
that surgical intervention aimed to retrieve the capsule can be
done in a laparoscopic way [66] and that BAE can also allow
capsule retrieval when surgical intervention is contraindicated or
not feasible [67,68]. In addition, the recently developed Patency
capsule [69] (Given Imaging, Yoqneam, Israel) can be used in
selected patients as a screening method to prevent capsule
retention.
The capsule can also have some problems in sizing lesions
because of the shape of its dome, its magnification capability, the
lack of air insufflated and of remote orientation. This issue has
recently been highlighted in papers addressed to study patients
with small-bowel inherited polyposis syndromes [70-71] in which
the authors found that MRI seems to be more accurate and
reliable than CE in the estimation of location and size of
polyps [71]. The ingestion of “reference granules” of mesalazine
15-20 minutes before CE has recently been proposed to increase
the accuracy of the procedure [72].
Another general limitation, that can be critical in the field of small-
bowel tumors, is the accurate localization of the lesion along the
small bowel. To estimate the location of a lesion we can correlate
the time when the lesion appears to the small-bowel transit time
divided in three equal thirds [73], or we can refer to the localization
system [74]; both these systems are time-consuming, depend on
some reference points established by the reader, are not suitable
when the capsule does not reach the ileo-cecal valve during
examination time and the localization software is reliable only
considering a two dimension plan. Despite all these obvious limi-
tations, in one large study [39] the capsule was able to correctly
estimate the location of the lesion in a surprisingly high percen-
tage of patients (about 85%).
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with Lynch syndrome [91]. The clinical utility of systematic small-
bowel screening in these patients should be accessed through
large prospective studies.
❚ Conclusions
Small-bowel tumors are a small but significant proportion of GI
neoplasms. Using new diagnostic modalities, their frequency has
been shown to be slightly superior than previously thought. Until
recently, diagnosis and management of these tumors were
delayed by the difficulty of access to the small bowel and the poor
diagnostic capabilities of the available diagnostic techniques. An
array of new methods has recently been developed, increasing
the possibility of detecting these tumors at an earlier stage.
Despite its limitations, CE plays a pivotal role in this setting.
Whether the use of CE in combination with other new diagnostic
(MRI or multidetector CT enterography) and therapeutic (BAE)
techniques will lead to earlier diagnosis and treatment of these
neoplasms, ultimately resulting in a survival advantage and in cost
savings, remains to be determined through carefully designed
studies.
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proposed in patients with inherited polyposis syndromes for both
surveillance over time and in case of symptomatic disease.
In Peutz-Jeghers syndrome (PJS) the polyps are chiefly located in
the small bowel (Fig. 3) and may give rise to complications in the
form of intussusception, bleeding and obstruction of the intestine,
depending on the number and size of the polyps present, as well
as to small-bowel malignancy. Several studies have explored the
possible diagnostic role of CE in these patients [70,71,80,81]
showing that this tool seems to be superior to small-bowel follow-
through [70]. Unfortunately, the same studies also underlined that
CE (as discussed above) is not reliable for accurate sizing of
polyps. At the present time it is suggested that CE should be
performed at diagnosis in all patients with PJS, as the primary
surveillance modality every 2-3 years from the age of 10, and as
part of the investigation of patients with symptoms [60]. Additional
information to evaluate the size and location of polyps, which is
useful for planning the appropriate therapeutic strategy, can be
provided by CT/MRI [70,71]. The coupling of CE with BAE and
polypectomy may offer an ideal follow-up and treatment method
for these patients, possibly avoiding surgery [82], or allowing for
better locating the small bowel lesions when a laparoscopic
approach is planned [83-85].
The role of CE is less clear in familial adenomatous poly-
poses (FAP). CE may miss duodenal/periampullary polyps due to
a quick passage of the device in the descending duodenum. In a
recently published prospective study, Wong et al. [86] compared
CE with push enteroscopy and with lower GI endoscopy in
32 patients with FAP. They showed that, in a defined segment of
the small bowel, CE diagnosed significantly fewer small-bowel
polyps than standard endoscopy, showed only fair agreement
with PE in determining polyp counts, and was fairly inaccurate in
determining the size of the largest polyp and also in detecting
large polyps. Recently Katsinelos et al. [87] described a similar
situation in a small series of patients with FAP. Although duodenal
adenomatous polyps were found in 64.3% patients, and jejunal
and ileal polyps in 50% and in 57.1% of patients, respectively, the
identification of the ampulla of Vater was not achieved with CE
and, importantly, the findings of CE had no immediate impact on
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